We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam Falls on Pfizer's Rare Disease Drug Success
Read MoreHide Full Article
Alnylam Pharmaceuticals, Inc.’s (ALNY - Free Report) shares fell 8.3% after pharma giant Pfizer Inc. (PFE - Free Report) announced positive top-line results from a late-stage study on a competing rare disease candidate.
Pfizer announced that a phase III ATTR-ACT study evaluating pipeline candidate tafamidis for a transthyretin cardiomyopathy, which is tied to progressive heart failure, met the primary endpoint. The condition belongs to a family of diseases called transthyretin amyloidosis, or ATTR.
Top-line data from the ATTR-ACT study showed that treatment with tafamidis led to a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations — the primary endpoint — compared with the placebo at 30 months. The safety data also demonstrated that that tafamidis was generally well tolerated by patients.
Currently, there are no approved medications in the United States for the treatment of transthyretin cardiomyopathy.
Shares of Alnylam plunged on this news as it increases competitive pressure on Alnylam’s lead candidate patisiran which has been developed for hereditary TTR amyloidosis, or hATTR. Patisiran is under review in the EU and United States (PDUFA date of Aug 11, 2018) and might be launched this year.
There are two types of TTR-CM, a hereditary form and a wild-type form of the disease, which is not hereditary. The ATTR-ACT study included both types of patients. However, Alnylam has developed patisiran for the hereditary form of the disease.
Note that shares of Ionis Pharmaceuticals, Inc. (IONS - Free Report) also fell on the announcement of the positive data by Pfizer, as the Ionis’ candidate inotersenis also under review for hereditary ATTR amyloidosis with polyneuropathy.
Regeneron’s earnings per share estimates have moved up from $18.65 to $18.68 for 2018 in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this year, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
Alnylam Falls on Pfizer's Rare Disease Drug Success
Alnylam Pharmaceuticals, Inc.’s (ALNY - Free Report) shares fell 8.3% after pharma giant Pfizer Inc. (PFE - Free Report) announced positive top-line results from a late-stage study on a competing rare disease candidate.
Pfizer announced that a phase III ATTR-ACT study evaluating pipeline candidate tafamidis for a transthyretin cardiomyopathy, which is tied to progressive heart failure, met the primary endpoint. The condition belongs to a family of diseases called transthyretin amyloidosis, or ATTR.
Top-line data from the ATTR-ACT study showed that treatment with tafamidis led to a statistically significant reduction in the combination of all-cause mortality and frequency of cardiovascular-related hospitalizations — the primary endpoint — compared with the placebo at 30 months. The safety data also demonstrated that that tafamidis was generally well tolerated by patients.
Currently, there are no approved medications in the United States for the treatment of transthyretin cardiomyopathy.
Shares of Alnylam plunged on this news as it increases competitive pressure on Alnylam’s lead candidate patisiran which has been developed for hereditary TTR amyloidosis, or hATTR. Patisiran is under review in the EU and United States (PDUFA date of Aug 11, 2018) and might be launched this year.
There are two types of TTR-CM, a hereditary form and a wild-type form of the disease, which is not hereditary. The ATTR-ACT study included both types of patients. However, Alnylam has developed patisiran for the hereditary form of the disease.
Note that shares of Ionis Pharmaceuticals, Inc. (IONS - Free Report) also fell on the announcement of the positive data by Pfizer, as the Ionis’ candidate inotersenis also under review for hereditary ATTR amyloidosis with polyneuropathy.
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. Price | Alnylam Pharmaceuticals, Inc. Quote
Zacks Rank & Stock to Consider
Alnylam carries a Zacks Rank #4 (Sell). Shares of the company rallied 136.1% in the past one year against the industry’s decline of 5.1%.
Investors interested in the space can consider a better-ranked stock Regeneron Pharmaceuticals (REGN - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates have moved up from $18.65 to $18.68 for 2018 in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this year, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>